Solid Biosciences Inc./$SLDB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Solid Biosciences Inc.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
Ticker
$SLDB
Sector
Primary listing
Employees
121
Headquarters
Website
SLDB Metrics
BasicAdvanced
$694m
-
-$1.99
2.76
-
Price and volume
Market cap
$694m
Beta
2.76
52-week high
$8.87
52-week low
$2.41
Average daily volume
985k
Financial strength
Current ratio
6.138
Quick ratio
5.612
Long term debt to equity
10.587
Total debt to equity
11.755
Profitability
EBITDA (TTM)
-177.57
Management effectiveness
Return on assets (TTM)
-53.18%
Return on equity (TTM)
-109.90%
Valuation
Price to book
3.09
Price to tangible book (TTM)
3.09
Price to free cash flow (TTM)
-3.918
Free cash flow yield (TTM)
-25.52%
Free cash flow per share (TTM)
-1.799
Growth
Earnings per share change (TTM)
-34.79%
3-year earnings per share growth (CAGR)
-41.79%
10-year earnings per share growth (CAGR)
-33.29%
SLDB News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Solid Biosciences Inc. stock?
Solid Biosciences Inc. (SLDB) has a market cap of $694M as of May 01, 2026.
What is the P/E ratio for Solid Biosciences Inc. stock?
The price to earnings (P/E) ratio for Solid Biosciences Inc. (SLDB) stock is 0 as of May 01, 2026.
Does Solid Biosciences Inc. stock pay dividends?
No, Solid Biosciences Inc. (SLDB) stock does not pay dividends to its shareholders as of May 01, 2026.
When is the next Solid Biosciences Inc. dividend payment date?
Solid Biosciences Inc. (SLDB) stock does not pay dividends to its shareholders.
What is the beta indicator for Solid Biosciences Inc.?
Solid Biosciences Inc. (SLDB) has a beta rating of 2.76. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.